Argenx uses cookies on this site to enhance your user experience. More information I AGREE Events Contact Home About us Products Partnering Investors News argenx advances a clinical pipeline to treat patients with cancer and severe autoimmune diseases argenx R&D day - 22 September 2016, New York. 9:00 AM EDT (3:00 PM CET) - Click here for the presentation. argenx in short argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. Human antibodies for novel targets and underserved diseases argenx develops novel human antibody medicines to unlock novel & complex targets addressing diseases that are underserved by current therapies. We combine our unique antibody discovery platform, SIMPLE Antibody™ with Fc engineering technologies to create highly differentiated antibodies with distinctive therapeutic qualities. Company news argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York September 22, 2016 argenx to host inaugural R&D day and webcast on September 22, 2016 September 15, 2016 Upcoming events argenx R&D Day: Developing Antibodies of Choice for Severe Auto-Immune Diseases and Oncology September 22, 2016 Oppenheimer Life Sciences Summit November 29, 2016 All news All events Product pipeline argenx creates antibodies with first- and best-in-class therapeutic potential. We have a diversified pipeline with two potential oncology drugs in the clinic, two autoimmune assets in the clinic and several product leads in preclinical development. ONCOLOGY AUTOIMMUNITY Read more Partnering opportunities Collaboration agreements with pharmaceutical companies enable argenx to provide our expertise to our partners and develop therapeutic antibody candidates in multiple disease areas. We are also accessing truly novel targets through partnerships with academic research groups under our Innovative Access Program. PARTNERSHIPS INNOVATIVE ACCESS PROGRAM Read more Stock info 01:58 - September 23, 2016 € 15.10 -0.15 -0.98 % Read more argenx R&D day - 22 Sept 9:00 AM EDT Replay is now available Financial calendar HY 2016 Financial results and Q2 Business update August 26, 2016 Q3 2016 Business update and Financial results October 27, 2016 Innovative Access Program Collaboration opportunities under our Innovative Access Program Downloads Corporate presentation Annual report 2015 Show all downloads Contact argenx N.V. Breda, The Netherlands T +31 763 030 488 info@argenx.com argenx BVBA Zwijnaarde, Belgium T +32 9 310 34 00 Downloads Webcast Presentation R&D day IAP flyer Corporate presentation Follow us 2016 © argenx | Disclaimer | Cookie policy | Sitemap Home About us Products Partnering Investors News Created by Cantilis